Skip to main content
. 2022 Mar 9;13:1219. doi: 10.1038/s41467-022-28727-5

Fig. 2. 89Zr-VRC01 uptake is preferentially increased in participants with HIV compared with uninfected controls.

Fig. 2

a Representative axial PET-MR images with inset magnification of bilateral inguinal lymph nodes on imaging day 3 for a viremic (V), ART-suppressed (A) and uninfected control (C). b Axial image of persistent inguinal lymph node 89Zr-VRC01 uptake in inguinal lymph nodes on imaging day 0 (6 h post injection), and imaging day 3 (72 h post injection) (b). rSUVmax and rSUV mean values for c inguinal and d axillary lymph node uptake averaged across bilateral nodes at imaging day 0, day 1, and day 3. Participant A1 (green triangle) started ART approximately 3 months prior PET imaging (early treatment initiation). ART suppressed participants were imaged starting on day 3 as per study protocol. SUV standardized uptake value, rSUV blood pool-adjusted 89Zr-VRC01 standardized uptake value (tissue to blood pool SUV ratio); P values <0.05 and <0.01 represented by * and **, respectively from two-sided non-parametric analyses (Mann–Whitney tests for analyses involving two groups and Kruskal–Wallis tests for analyses involving three groups). Mean and standard error bars are shown. Control N = 4 on day 0 and day 1, viremic case N = 4 and 3 on day 0 and day 1, respectively (‡statistical analyses not performed on day 1 as one viremic participant missed this visit). Control and viremic and ART case N = 5 on day 3. Source data are provided as a Source Data file.